|
| 產(chǎn)地 | 進(jìn)口、國產(chǎn) |
| 品牌 | 上海莼試 |
| 保存條件 | Store at -20 °C |
| 貨號(hào) | CS10711 |
| 應(yīng)用范圍 | ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500 |
| CAS編號(hào) | |
| 抗體名 | Anti-Phospho-PRK1 (Thr774)/PRK2 (Thr816) |
| 克隆性 | |
| 靶點(diǎn) | 詳見說明書 |
| 適應(yīng)物種 | 詳見說明書 |
| 形態(tài) | 詳見說明書 |
| 宿主 | 詳見說明書 |
| 亞型 | IgG |
| 標(biāo)識(shí)物 | 詳見說明書 |
| 濃度 | 1mg/1ml% |
| 免疫原 | KLH conjugated synthesised phosphopeptide derived from human PRK1 around the phosphorylation site of Thr774 |
產(chǎn)品訂購信息：
英文名稱 Anti-Phospho-PRK1 (Thr774)/PRK2 (Thr816)
中文名稱 磷酸化腺衍生內(nèi)皮生長因子抗體品牌
別 名 Prokineticin-1/Endocrine-gland-derived vascular endothelial growth factor; PROK1; EGVEGF; PK1; EG-VEGF; PRK1.
濃 度 1mg/1ml
規(guī) 格 0.1ml/100μg
抗體來源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit
產(chǎn)品類型 一抗 磷酸化抗體
研究領(lǐng)域 免疫學(xué) 內(nèi)皮細(xì)胞
蛋白分子量 predicted molecular weight: 103kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthesised phosphopeptide derived from human PRK1 around the phosphorylation site of Thr774
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
磷酸化腺衍生內(nèi)皮生長因子抗體品牌 產(chǎn)品應(yīng)用 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
產(chǎn)品介紹 Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) induces proliferation, migration, and fenestration in capillary endothelial cells derived from endocrine glands. EG-VEGF possesses an HIF-1 binding site; its expression is induced by hypoxia and restricted to the steroidogenic glands (ovary, testis, adrenal and placenta). Expression of EG-VEGF is often complementary to the expression of VEGF, suggesting that these molecules function in a coordinated manner. EG-VEGF is an example of a class of highly specific mitogens that act to regulate proliferation and differentiation of the vascular endothelium in a tissue-specific manner. It is expressed primarily in one type of tissue and acts selectively on one type of endothelium. EG-VEGF, possibly through binding to a G protein-coupled receptor, results in the activation of MAPK p44/42 and phosphatidylinositol 3-kinase signaling pathways, leading to proliferation, migration and survival of responsive endothelial cells .
Function : Endocrine gland-derived vascular endothelial growth factor (EG-VEGF) induces proliferation, migration, and fenestration in capillary endothelial cells derived from endocrine glands. Its expression is induced by hypoxia and is restricted to the steroidogenic glands (ovary, testis, adrenal, and placenta). Its expression is often complementary to the expression of VEGF (MIM192240), suggesting that these molecules function in a coordinated manner.[supplied by OMIM].
Subcellular Location : Cytoplasm. Nucleus. Endosome. Cell membrane; Peripheral membrane protein.
Tissue Specificity : Found ubiquitously. Expressed in heart, brain, placenta, lung, skeletal muscle, kidney and pancreas.
Anti-CD272/BTLA/FITC 熒光素標(biāo)記B和T淋巴細(xì)胞衰減蛋白抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Anti-IL-6/FITC (mouse、rat) 熒光素標(biāo)記白介素6抗體IgGMulti-class antibodies規(guī)格： 0.2ml
Rhesus antibody Rh CD24 CD24抗體 規(guī)格 0.1ml
MMP-17(Matrix metalloproteinase-17) 基質(zhì)金屬蛋白酶-17抗原 0.5mg
IFI44L 英文名稱： 干擾素誘導(dǎo)蛋白44樣蛋白抗體 0.2ml
Rhesus antibody Rh STK25/YSK1 絲氨酸/蘇氨酸激酶25抗體 規(guī)格 0.2ml
Anti-IL-6/FITC (mouse、rat) 熒光素標(biāo)記白介素6抗體IgGMulti-class antibodies規(guī)格： 0.2ml
AQP-0(Human Aquaporin 0) ELISA Kit 人水通道蛋白0Multi-class antibodies規(guī)格： 48T
Anti-Phospho-SEK1/MKK4 (Ser257) 磷酸化原活化蛋白激酶激酶4抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh HSPC117/C22orf28 22號(hào)染色體開放閱讀框28抗體 規(guī)格 0.2ml
PL12/AlaRS(Human anti-PL12-antibody) ELISA Kit 人PL12抗體/抗丙酰tRNA合成酶 96T
PPP4C 英文名稱： 絲酸/蘇酸蛋酸酶4C抗體 0.2ml
CCDC153 英文名稱： 卷曲螺旋結(jié)構(gòu)域蛋白153抗體 0.2ml
Anti-Phospho-SEK1/MKK4 (Ser257) 磷酸化原活化蛋白激酶激酶4抗體Multi-class antibodies規(guī)格： 0.1ml
Alpha-GST ELISA Kit 大鼠α谷胱甘肽S轉(zhuǎn)移酶Multi-class antibodies規(guī)格： 48T
Anti-TRIM32 TRIM32抗體Multi-class antibodies規(guī)格： 0.1ml
Rhesus antibody Rh GIMAP5 GTP酶IMAP家族成員5抗體 規(guī)格 0.2ml
CA-2(Mouse carbonic anhydrase 2) ELISA KIT 小鼠酶2 96T
Phospho-NMDAR2A (Tyr1325) 英文名稱： 磷酸化谷酸受體2A抗體 0.1ml
ALS2CR8 英文名稱： 肌側(cè)索硬化2染色體區(qū)域候選蛋白8抗體 0.2ml
Anti-TRIM32 TRIM32抗體Multi-class antibodies規(guī)格： 0.1ml
CL-0103Hep G2(人細(xì)胞)5×106cells/瓶×2
IgG2a Others Mouse 小鼠 IgG2a-Fc 人細(xì)胞裂解液 (陽性對照)
小鼠肝竇內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL
RAG小鼠腎腺癌細(xì)胞 RAG mice renal adenocarcinoma cells MEM培養(yǎng)基(GIBCO)+10%FBS
LIF Protein Mouse 重組小鼠 LIF 蛋白 (Fc 標(biāo)簽)
RTE(大鼠氣管上皮細(xì)胞) 5×106cells/瓶×2 A375(人類惡性)
CL-0100HEC-1-B(人子宮內(nèi)膜腺癌細(xì)胞)5×106cells/瓶×2
CSF2RB Others Rat 大鼠 CD131 / CSF2RB / IL3RB / IL5RB 人細(xì)胞裂解液 (陽性對照)
人海馬趾星形膠質(zhì)細(xì)胞裂解物HA-h L
OVCaR-3細(xì)胞，人細(xì)胞 菜青蟲卵巢細(xì)胞,Pr-HNV8細(xì)胞 神經(jīng)膠質(zhì)細(xì)胞Many types of cells包裝：5 × 105次方(1ml)
CEM/C1(人急性淋巴細(xì)胞細(xì)胞) 5×106cells/瓶×2
HUtSMC Pellet 人細(xì)胞團(tuán)塊 > 1 mio.cells 人表皮角質(zhì)細(xì)胞-cDNAHEK-acDNA
磷酸化腺衍生內(nèi)皮生長因子抗體品牌 IGFBP6 Others Human 人 IGFBP6 / IBP-6 人細(xì)胞裂解液 (陽性對照)
人口腔角質(zhì)細(xì)胞裂解物HOKL
BRL-3A 大鼠正常肝細(xì)胞
CL-0118HT-29(人細(xì)胞)5×106cells/瓶×2
人絨毛間充質(zhì)成纖維細(xì)胞
人肝永生化細(xì)胞;THLE-3 人微內(nèi)皮細(xì)胞完全培養(yǎng)基 100mL
抗體的生物素化標(biāo)記實(shí)驗(yàn)要點(diǎn)：
1. 磷酸化腺衍生內(nèi)皮生長因子抗體品牌 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會(huì)抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；
2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會(huì)有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個(gè)不同的分子比來篩選最適條件；
3.用NHSB量過量也是不利的,抗原的結(jié)合位點(diǎn)可能因此被封閉,導(dǎo)致抗體失活；
4.由于抗體的氨基不易接近可能造成生物素化不足,此時(shí)可加入去污劑如 Triton x-100, Tween20等；
5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點(diǎn)時(shí),或位于酶的催化位點(diǎn)時(shí),生物素化會(huì)降低或損傷抗體蛋白的結(jié)合力或活性；
6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及*基,也可與糖基共價(jià)結(jié)合；
7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會(huì)對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；
8.在細(xì)胞的熒光標(biāo)記實(shí)驗(yàn)中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。
抗體的鑒定：
1）磷酸化腺衍生內(nèi)皮生長因子抗體品牌 抗體的效價(jià)鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價(jià)。不同的抗原制備的抗體,要求的效價(jià)不一。鑒定效價(jià)的方法很多,包括有試管凝集反應(yīng),瓊脂擴(kuò)散試驗(yàn),酶聯(lián)免疫吸附試驗(yàn)等。常用的抗原所制備的抗體一般都有約成的鑒定效價(jià)的方法,以資比較。如制備抗抗體的效價(jià),一般就采用瓊脂擴(kuò)散試驗(yàn)來鑒定。
2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識(shí)別能力。抗體的特異性高,它的識(shí)別能力就強(qiáng)。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗(yàn)測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計(jì)算各自的結(jié)合率,求出各自在IC50時(shí)的濃度,并按公式計(jì)算交叉反應(yīng)率。
如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時(shí),表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。
3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點(diǎn)與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測定對抗體的篩選,確定抗體的用途,驗(yàn)證抗體的均一性等均有重要意義。
|
|
|
|
|
